Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.52 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.52 |
| ▸ | APAF1 | O14727 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1415431 | 0.85 | SCN9A (0.50) | MAOAMAOBMAPTMEN1KMT2A | |
| SCHEMBL1415877 | 0.82 | FGFR2 (0.42) | — | |
| SCHEMBL16655993 | 0.82 | NR4A1 (0.44) | ALDH1A1CYP3A4TSHRSCN9AKCNH2 | |
| SCHEMBL1459485 | 0.82 | MAOB (0.56) | MAOBALDH1A1CYP3A4TSHRMAPT | |
| SCHEMBL20067699 | 0.81 | MAPT (0.44) | MAOAMAOBTSHRMAPTSMN1; SMN2 | |
| SCHEMBL191885 | 0.81 | CCR1 (0.47) | ALDH1A1MEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL1415532 | 0.81 | S1PR2 (0.46) | CYP3A4MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8237311 | 0.81 | TEAD4 (0.44) | ALDH1A1TDP1MAPTMEN1KMT2A | |
| SCHEMBL16029077 | 0.81 | LOX (0.40) | MEN1KMT2ASCN9AKCNH2SCN5A | |
| SCHEMBL190319 | 0.81 | LTA4H (0.48) | MAOBTDP1TSHRMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230339891-A1 | URACIL DERIVATIVES AS MER-AXL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2019141980-A1 | AGRICULTURAL CHEMICALS | GLOBACHEM NV (BE) | 2019-07-25 | — | — | WO | disclosed |
| EP-2473501-B1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-2473501-B1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-9902709-B2 | Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition | PEKING UNIVERSITY FOUNDER GROUP CO., LTD. (CN) | 2018-02-27 | — | — | US | disclosed |
| US-9902709-B2 | Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition | PEKING UNIVERSITY FOUNDER GROUP CO., LTD. (CN) | 2018-02-27 | — | — | US | disclosed |
| US-9902709-B2 | Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition | PEKING UNIVERSITY FOUNDER GROUP CO., LTD. (CN) | 2018-02-27 | — | — | US | disclosed |
| US-9725433-B2 | Compounds as tyrosine kinase modulators | ALLERGAN, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725433-B2 | Compounds as tyrosine kinase modulators | ALLERGAN, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20070117817-A1 | 4-{3-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy}-N-methylpyridine-2-carboxamide;anticarcinogenic agents; breast cancer; antitumor agents; respiratory system disorders; urogenital disorders; gastrointestinal disorders; skin disorders; glandular disorders; lymphomas; leukemia; cytolysis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070117817-A1 | 4-{3-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy}-N-methylpyridine-2-carboxamide;anticarcinogenic agents; breast cancer; antitumor agents; respiratory system disorders; urogenital disorders; gastrointestinal disorders; skin disorders; glandular disorders; lymphomas; leukemia; cytolysis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070117817-A1 | 4-{3-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy}-N-methylpyridine-2-carboxamide;anticarcinogenic agents; breast cancer; antitumor agents; respiratory system disorders; urogenital disorders; gastrointestinal disorders; skin disorders; glandular disorders; lymphomas; leukemia; cytolysis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-24 | — | — | US | disclosed |
| WO-2006099231-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-09-21 | — | — | WO | disclosed |
| EP-1689722-A2 | 4-AMINOPYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | FLOERSHEIMER ANDREAS | 2006-06-15 | — | — | US | disclosed |
| US-20050277640-A1 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-12-15 | — | — | US | disclosed |
| WO-2005035507-A2 | 4-AMINOPYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-04-21 | — | — | WO | disclosed |
| EP-1511730-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003099771-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | MERTK, DAPK1, AXL | MAOA 3813/4885MAOB 3630/4885ALDH1A1 1072/4885 |
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | UCK2, PRKDC, PRKACA | MAOA 2466/4885MAOB 2320/4885ALDH1A1 3040/4885 |
| US-20070117817-A1 | 4-{3-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy}-N-methylpyridine-2-carboxamide;anticarcinogenic agents; breast cancer; antitumor agents; respiratory system disorders; urogenital disorders; gastrointestinal disorders; skin disorders; glandular disorders; lymphomas; leukemia; cytolysis | CCNA2, MALT1, TPD52L2 | MAOA 584/4885MAOB 636/4885ALDH1A1 1614/4885 |
| US-20050277640-A1 | Pyrimidine derivatives for treatment of hyperproliferative disorders | TYMP, DPYD, CCNA2 | MAOA 1999/4885MAOB 958/4885ALDH1A1 1122/4885 |
| US-20230339891-A1 | URACIL DERIVATIVES AS MER-AXL INHIBITORS | MERTK, DAPK1, AXL | MAOA 3813/4885MAOB 3630/4885ALDH1A1 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.